**Radiopharmaceuticals in Advanced Prostate Cancer: Recent Advances in Imaging and Treatment Utilizing PSMA**

Abstract: Recent advances in the use of radiopharmaceuticals and, in particular, those utilizing the PSMA prostate cell target, are now playing a critical role in the diagnosis and treatment of men with metastatic prostate cancer. I will be reviewing recent trials and data showing the benefits that these radiopharmaceuticals provide.

Bio: Gregg Franklin is a board-certified radiation oncologist and currently serves as the medical director of radiation oncology at the New Mexico Cancer Center. Prior to working at the New Mexico Cancer Center since 2005, he completed his residency at Washington University/Barnes Jewish Hospital in St. Louis, Missouri. Prior to his MD degree, Dr. Franklin earned a Ph.D. in condensed matter physics at the University of Illinois at Urbana-Champaign. Between these degrees, from 1992 through 1996, he was a postdoctoral fellow at Harvard University and a scientist with Sandia National Laboratory in Albuquerque, NM. He is currently a fellow with the American Society for Radiation Oncology (ASTRO), American College of Radiology (ACR) and with the American Society for Clinical Oncology College of Radiation Oncology (ASCO).